We offer a complete line of in silico and in vitro services for manufacturability, immunogenicity, humanization, and protein engineering. These technologies include our award winning and patented Epibase® T cell epitope screening platform for immunogenicity assessment along with our proprietary technology platform for structural protein engineering. Our Cambridge, UK-based Applied Protein Services scientists will help you determine a testing strategy, analyze and interpret the data, and recommend next steps throughout the process.
Lonza’s protein design and optimization services were developed to mitigate risks, reduce attrition, and improve the quality and safety of therapeutic proteins. They also address the challenges and accelerate the design and development of efficacious vaccines. These services provide a complete portfolio for your late discovery and early development needs.
In addition to our protein design and optimization services, we also offer a protein production service for mg to kg quantities of both non-GMP and cGMP material. Lonza’s Light Path™ programs are streamlined and minimal scope development and manufacturing services available for both mammalian and microbial applications.
In silico, in vitro PTM prediction and testing, Antibody aggregation propensity prediction. Protein re-engineering to improve developability
Detection of Innate Immune Response Modulating Impurities of protein therapeutics caused by process impurities, degradation, or formulation changes.
T cell epitope prediction
Epibase in silico T cell epitope prediction from protein sequences. Applied to avoid unwanted immunogenicity for therapeutic proteins and wanted immunogenicity for vaccines
A wide range of cellular assays using Human PBMCs to identify protein Immunogenicity risk
Reducing antibody immunogenicity by removing T helper epitopes
Lonza De-risking & Development Services has not received any reviews.
Lonza De-risking & Development Services has not received any endorsements.